Taltz

Taltz

ixekizumab

Manufacturer:

Eli Lilly

Distributor:

Zuellig
/
Agencia Lei Va Hong
Concise Prescribing Info
Contents
Ixekizumab
Indications/Uses
Moderate to severe plaque psoriasis in adults who are candidates for systemic therapy. Monotherapy or in combination w/ methotrexate for the treatment of active psoriatic arthritis in adult patients who have responded inadequately to, or who are intolerant to ≥1 disease-modifying anti-rheumatic drug (DMARD) therapies.
Dosage/Direction for Use
SC Plaque psoriasis Recommended dose: 160 mg (2 inj) at wk 0, then 80 mg (1 inj) at wk 2, 4, 6, 8, 10 & 12, then maintenance dosing of 80 mg (1 inj) every 4 wk. Psoriatic arthritis Recommended dose: 160 mg (2 inj) at wk 0, then 80 mg (1 inj) every 4 wk thereafter.
Contraindications
Serious hypersensitivity. Clinically important active infections eg, active TB.
Special Precautions
Serious hypersensitivity reactions. Increased rate of infections eg, upper resp tract infection, oral candidiasis, conjunctivitis, & tinea infections. Exercise caution & closely monitor patients w/ inflammatory bowel disease, eg, Crohn's disease & ulcerative colitis. Do not use w/ live vaccines. Women of childbearing potential should use effective method of contraception during & for at least 10 wk after treatment. Pregnancy & lactation. Childn & adolescents 6-18 yr.
Adverse Reactions
Upper resp tract infections; inj site reactions. Tinea infection, herpes simplex (mucocutaneous); oropharyngeal pain; nausea.
Drug Interactions
Normalisation of CYP450 levels w/ accompanying lower exposure of CYP450-metabolised co-medications.
MIMS Class
Immunosuppressants
ATC Classification
L04AC13 - ixekizumab ; Belongs to the class of interleukin inhibitors. Used as immunosuppressants.
Presentation/Packing
Form
Taltz soln for inj 80 mg/mL
Packing/Price
1's
Exclusive offer for doctors
Register for a MIMS account and receive free medical publications worth $768 a year.
Sign up for free
Already a member? Sign in